BioNxt Solutions Secures Key European Patent for Drug Delivery Technology

BioNxt Solutions stock rose over 12% after securing a key European unitary patent for its lead drug BNT23001, a sublingual film for MS treatment, streamlining its path to market.

Shares of BioNxt Solutions experienced a notable surge on the Canadian Securities Exchange this week, climbing over 12 percent at one point during Tuesday's session. This market movement followed a significant corporate development: the formal registration of a unitary European patent for the company's lead pharmaceutical candidate.

A Strategic Milestone for Commercialization

The company announced the official registration of European Patent EP4539857, which provides unified protection for its sublingual thin-film formulation of Cladribine, known as BNT23001. This patent is now valid across 18 European Union member states, including major markets such as Germany, France, and Italy. For a biotechnology firm of BioNxt's size, this represents a crucial step toward bringing its technology to market.

The European unitary patent system offers a distinct strategic advantage by streamlining legal processes. Instead of navigating separate validation and enforcement procedures in each country, a single legal framework covers all participating nations. This substantially reduces administrative complexity and cost, making the company a more attractive potential partner for licensing and collaborative development deals. Chief Executive Hugh Rogers highlighted that this registration establishes the foundation for pursuing such partnership agreements within Europe.

Inside the Patent and Technology

The patented technology, BNT23001, utilizes a fast-dissolving film placed under the tongue. This delivery method allows the active drug, Cladribine, to be absorbed directly through the mucous membranes in the mouth, bypassing the gastrointestinal tract entirely. In preclinical studies, this formulation demonstrated a systemic exposure profile comparable to the already-approved reference product Mavenclad®, and did so without generating treatment-related adverse effects.

According to the European Patent Office, the patent was registered on March 31, 2026, with an effective date of March 11, 2026.

Pipeline Extends Beyond Multiple Sclerosis

While BNT23001 is targeted for Multiple Sclerosis, BioNxt's development pipeline contains several other promising candidates. The company is also developing BNT23002 for Myasthenia Gravis, BNT24002 for Lupus Nephritis, and BNT24003 for Rheumatoid Arthritis. Furthermore, the pipeline includes a candidate therapy based on Semaglutid.

The Path Forward: Human Trials

The immediate next milestone for the lead candidate is a human bioavailability study. This trial will directly compare the company's oral dissolvable film (ODF) formulation with the currently marketed tablet version. The outcome of this study is pivotal; it will determine whether the promising preclinical data can be translated into clinically relevant evidence. Success here is a prerequisite for a complete regulatory submission to European authorities.

This patent grant effectively de-risks a portion of BioNxt's European strategy, providing clearer intellectual property protection as the company advances its clinical programs.